DAPK3/ZIPK Antibody #2928
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 52 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Background
The DAPK family consists of several kinases including DAPK, DAPK2/DRP-1 (6), and DAPK3/ZIPK/DLK (7-9) with homology in their catalytic domain. Overexpression of DAPK3/ZIPK, but not a catalytically inactive mutant, can induce apoptosis (7). DAPK3 was also identified as a myosin light chain kinase, demonstrating ability to phosphorylate the regulatory light chain of myosin II in a Ca2+/calmodulin-independent manner (8). In addition to an amino-terminal kinase domain, DAPK3 contains a carboxy-terminal leucine zipper domain that mediates interaction with leucine zipper transcription factors such as ATF4 (7). DAPK3 is predominantly localized to the nucleus and has been found in PML oncogenic domains (PODs) associated with DAXX and PAR-4, and can phosphorylate PAR-4 in vitro (10,11). In addition, DAPK3 can phosphorylate STAT3 at Ser727 to enhance its transcriptional activity (12).
- Kimchi, A. (1999) Ann Rheum Dis. 58, I14-I19.
- Cohen, O. et al. (1999) J Cell Biol 146, 141-148.
- Deiss, L. P. et al. (1995) Genes Dev 9, 15-30.
- Cohen, O. et al. (1997) EMBO J 16, 998-1008.
- Velentza, A. V. et al. (2001) J Biol Chem 276, 38956-38965.
- Inbal, B. et al. (2000) Mol Cell Biol 20, 1044-54.
- Kawai, T. et al. (1998) Mol Cell Biol 18, 1642-51.
- Murata-Hori, M. et al. (1999) FEBS Lett 451, 81-4.
- Kögel, D. et al. (1998) Oncogene 17, 2645-54.
- Page, G. et al. (1999) Oncogene 18, 7265-73.
- Kawai, T. et al. (2003) Mol Cell Biol 23, 6174-86.
- Sato, N. et al. (2005) Int Immunol 17, 1543-52.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.